Dibenzo[f,h]pyrrolo[1,2-b]isoquinoline,9,11,12,13,13a,14-hexahydro-2,3,5,6-tetramethoxy-, (13aR)-

Suppliers

Names

[ Name ]:
Dibenzo[f,h]pyrrolo[1,2-b]isoquinoline,9,11,12,13,13a,14-hexahydro-2,3,5,6-tetramethoxy-, (13aR)-

[Synonym ]:
Tylocerebrine
[13aR,(+)]-9,11,12,13,13a,14-Hexahydro-2,3,5,6-tetramethoxydibenzo[f,h]pyrrolo[1,2-b]isoquinoline
(-)-(R)-tylocrebrine
Tylocrebrin
Dibenzo(F,H)pyrrolo(1,2-B)isoquinoline,9,11,12,13,13A,14-hexahydro-2,3,5,6-tetramethoxy-,(R)-(9ci)
Dibenzo(F,H)pyrrolo(1,2-B)isoquinoline,9,11,12,13,13A,14-hexahydro-2,3,5,6-tetramethoxy
Lylocrebrine
Tylocrebine

Chemical & Physical Properties

[ Density]:
1.26g/cm3

[ Boiling Point ]:
559.9ºC at 760 mmHg

[ Molecular Formula ]:
C₂₄H₂₇NO₄

[ Molecular Weight ]:
393.47500

[ Flash Point ]:
160.5ºC

[ Exact Mass ]:
393.19400

[ PSA ]:
40.16000

[ LogP ]:
4.48580

[ Vapour Pressure ]:
1.44E-12mmHg at 25°C

[ Index of Refraction ]:
1.657

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YP0175000

CHEMICAL NAME :: Tylocrebrine

CAS REGISTRY NUMBER :: 6879-02-3

LAST UPDATED :: 199612

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C24-H27-N-O4

MOLECULAR WEIGHT :: 393.52

WISWESSER LINE NOTATION :: T D5 B6 K666 DNJ MO1 NO1 RO1 SO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 65 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair

REFERENCE :: NCICP* Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co. Volume(issue)/page/year: -,77,1964

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 32 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Gastrointestinal - hypermotility, diarrhea

REFERENCE :: NCICP* Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co. Volume(issue)/page/year: -,77,1964

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Behavioral - ataxia Gastrointestinal - hypermotility, diarrhea

REFERENCE :: NCICP* Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co. Volume(issue)/page/year: -,77,1964

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 42 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia

REFERENCE :: NCICP* Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co. Volume(issue)/page/year: -,77,1964 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 12 mg/kg/24D-I

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of esophagus Gastrointestinal - ulceration or bleeding from large intestine Blood - other changes

REFERENCE :: NCICP* Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co. Volume(issue)/page/year: -,77,1964

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Primate - monkey

DOSE/DURATION :: 24 mg/kg/24D-I

TOXIC EFFECTS :: Liver - other changes Blood - pigmented or nucleated red blood cells Blood - changes in erythrocyte (RBC) count

REFERENCE :: NCICP* Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co. Volume(issue)/page/year: -,77,1964

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

1-bromo-2-iodo-4,5-dimethoxybenzene
(2,3-Dimethoxyphenyl)boronic acid

DownStream

Related Compounds

2-(4-{5,6-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperazin-1-yl)-4-(pyridin-4-yl)pyrimidine
1-{2-Tert-butylimidazo[1,2-b]pyridazin-6-yl}-4-[(5-cyclopropyl-1,2-oxazol-3-yl)methyl]-1,4-diazepane
7-(3,5-dimethoxybenzoyl)-6H,7H,8H,9H-pyrido[2,3-b]1,6-naphthyridine
2-benzyl-6-{4-[(4,5,6,7-tetrahydro-1H-indazol-3-yl)methyl]piperazin-1-yl}-2,3-dihydropyridazin-3-one
2-{3-[({2-tert-butylimidazo[1,2-b]pyridazin-6-yl}oxy)methyl]pyrrolidin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one
3-[({2-Tert-butylimidazo[1,2-b]pyridazin-6-yl}oxy)methyl]-1-{pyrido[3,4-d]pyrimidin-4-yl}pyrrolidine
2-[2-(4,4-difluoropiperidine-1-carbonyl)morpholin-4-yl]-N-(4-methylphenyl)acetamide
2-[2-(4,4-difluoropiperidine-1-carbonyl)morpholin-4-yl]-N-(3-methylphenyl)acetamide
N-(1-{[(4-ethoxyphenyl)carbamoyl]methyl}piperidin-4-yl)-2,2-dimethylpropanamide
2-[2-(4,4-difluoropiperidine-1-carbonyl)morpholin-4-yl]-N-(4-fluorophenyl)acetamide